IL149444A0 - A composition containing an angiotensin ii antagonist for the treatment of glaucoma - Google Patents

A composition containing an angiotensin ii antagonist for the treatment of glaucoma

Info

Publication number
IL149444A0
IL149444A0 IL14944400A IL14944400A IL149444A0 IL 149444 A0 IL149444 A0 IL 149444A0 IL 14944400 A IL14944400 A IL 14944400A IL 14944400 A IL14944400 A IL 14944400A IL 149444 A0 IL149444 A0 IL 149444A0
Authority
IL
Israel
Prior art keywords
angiotensin
glaucoma
antagonist
treatment
composition containing
Prior art date
Application number
IL14944400A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL149444A0 publication Critical patent/IL149444A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
IL14944400A 1999-12-01 2000-12-01 A composition containing an angiotensin ii antagonist for the treatment of glaucoma IL149444A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34152499 1999-12-01
JP2000078769 2000-03-21
PCT/JP2000/008545 WO2001039805A1 (en) 1999-12-01 2000-12-01 Concomitant drugs for treating glaucoma

Publications (1)

Publication Number Publication Date
IL149444A0 true IL149444A0 (en) 2002-11-10

Family

ID=26576988

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14944400A IL149444A0 (en) 1999-12-01 2000-12-01 A composition containing an angiotensin ii antagonist for the treatment of glaucoma
IL149444A IL149444A (en) 1999-12-01 2002-05-02 Preparation containing angiotensin II antagonist for the treatment of emphysema

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149444A IL149444A (en) 1999-12-01 2002-05-02 Preparation containing angiotensin II antagonist for the treatment of emphysema

Country Status (22)

Country Link
US (4) US7307096B2 (cs)
EP (3) EP1344535A3 (cs)
JP (1) JP4000505B2 (cs)
KR (3) KR20040045028A (cs)
CN (3) CN1615879A (cs)
AT (1) ATE332145T1 (cs)
AU (1) AU773110B2 (cs)
BR (1) BR0015980A (cs)
CA (1) CA2392804C (cs)
CZ (1) CZ20021829A3 (cs)
DE (1) DE60029242T2 (cs)
ES (1) ES2267586T3 (cs)
HK (1) HK1047239B (cs)
HU (1) HUP0204049A3 (cs)
IL (2) IL149444A0 (cs)
MX (1) MXPA02005505A (cs)
NO (1) NO20022584L (cs)
NZ (1) NZ518930A (cs)
PL (1) PL201783B1 (cs)
RU (4) RU2002114335A (cs)
TW (1) TWI290470B (cs)
WO (1) WO2001039805A1 (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0209063A (pt) * 2001-04-19 2004-08-10 Teika Pharmaceutical Co Ltd Medicamentos e kits de uso medicinal
TW200305424A (en) * 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
US20050119299A1 (en) * 2002-03-08 2005-06-02 Sankyo Company, Limited Ophthalmic solutions containing tetrazole derivatives
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
KR20120005052A (ko) * 2003-08-21 2012-01-13 수캄포 아게 안과용 조성물
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
WO2005079809A1 (ja) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. 澄明なラタノプロスト点眼液
CA2645311C (en) * 2006-03-13 2014-11-18 R-Tech Ueno, Ltd. Aqueous composition comprising 15-keto-prostaglandin for ophthalmic use
RU2339384C1 (ru) * 2007-10-18 2008-11-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Вискоэластик для защиты интраокулярных тканей
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
RU2411946C1 (ru) * 2009-07-06 2011-02-20 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Вископротектор для защиты интраокулярных тканей
EP2566453A4 (en) * 2010-05-07 2014-05-07 Sun Pharma Advanced Res Co Ltd NOVEL OPHTHALMIC COMPOSITIONS
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
CA2860453C (en) * 2011-01-24 2020-04-28 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
KR101327267B1 (ko) 2012-04-26 2013-11-11 한양대학교 에리카산학협력단 엔드이펙터용 구동력 전달장치
JP6686023B2 (ja) 2014-11-25 2020-04-22 エキシモア・リミテッドＥｘｉｍｏｒｅ Ｌｔｄ． 生物活性剤または生物活性剤類を送達する組成物および方法
MX2017007572A (es) * 2014-12-12 2018-02-09 Kowa Co Composicion acuosa.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619370A (en) 1969-04-21 1971-11-09 Frosst & Co Charles E Microbial reduction of thiadiazoles
JPS4966691A (cs) 1972-10-30 1974-06-27
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
DE3568431D1 (en) * 1984-12-12 1989-04-06 Merck & Co Inc Substituted aromatic sulfonamides, their preparation and ophthalmic compositions containing them
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
JP2610619B2 (ja) * 1987-07-22 1997-05-14 エーザイ株式会社 高眼圧症治療用点眼剤
JPS6426518U (cs) 1987-08-11 1989-02-15
EP1348437A3 (en) 1988-09-06 2003-11-19 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP0390883B1 (de) 1988-09-09 1994-12-07 DRAENERT, Klaus, Dr.med. Hüftgelenksprothese und ihre verwendung
EP0375299A1 (en) * 1988-12-19 1990-06-27 Merck & Co. Inc. Combinations of angiotensin converting enzyme, and carbonic anhydrase, inhibitors for treating glaucoma
US5273976A (en) * 1989-04-06 1993-12-28 Sankyo Company, Limited Ocular hypotensive agents
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
US5250521A (en) * 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
IL104648A0 (en) 1992-02-13 1993-06-10 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a prostaglandin or prostaglandin derivative
ES2118941T3 (es) * 1992-02-21 1998-10-01 Alcon Lab Inc Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta.
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
ATE300287T1 (de) * 1994-02-08 2005-08-15 Novartis Pharma Gmbh Behandlung von normaldruckglaukom mit valsartan
WO1995024902A1 (en) * 1994-03-16 1995-09-21 Sankyo Company, Limited Ocular tension depressant
CA2185524C (en) * 1994-03-16 2006-12-05 Sankyo Company Limited Ocular tension depressant
US5760249A (en) * 1995-08-29 1998-06-02 Merck & Co., Inc. Synthesis of hydroxysulfone and related compounds
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
US6107323A (en) * 1996-04-05 2000-08-22 Takeda Chemical Industries, Ltd. Pharmaceutical composition
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
CA2293325C (en) 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
ES2242619T3 (es) * 1999-06-11 2005-11-16 Sankyo Company, Limited Composicion para disminuir la tension ocular para la administracion topica.

Also Published As

Publication number Publication date
BR0015980A (pt) 2002-11-12
RU2002114335A (ru) 2004-01-10
HUP0204049A2 (hu) 2003-04-28
EP1344534A3 (en) 2004-01-02
WO2001039805A1 (en) 2001-06-07
NO20022584L (no) 2002-07-29
EP1234582A1 (en) 2002-08-28
AU773110B2 (en) 2004-05-20
NO20022584D0 (no) 2002-05-31
US7307096B2 (en) 2007-12-11
MXPA02005505A (es) 2002-09-02
JP2001335511A (ja) 2001-12-04
AU1557501A (en) 2001-06-12
US20050014808A1 (en) 2005-01-20
EP1344535A3 (en) 2004-01-28
RU2004111357A (ru) 2005-09-20
HK1047239A1 (en) 2003-02-14
DE60029242T2 (de) 2007-07-05
HUP0204049A3 (en) 2006-07-28
JP4000505B2 (ja) 2007-10-31
IL149444A (en) 2007-06-17
CN1407903A (zh) 2003-04-02
CZ20021829A3 (cs) 2002-08-14
DE60029242D1 (de) 2006-08-17
US20080221184A1 (en) 2008-09-11
CA2392804A1 (en) 2001-06-07
US20050043383A1 (en) 2005-02-24
NZ518930A (en) 2003-09-26
RU2299067C2 (ru) 2007-05-20
PL201783B1 (pl) 2009-05-29
KR20040045029A (ko) 2004-05-31
PL355431A1 (en) 2004-04-19
ATE332145T1 (de) 2006-07-15
CA2392804C (en) 2009-02-03
US20030040529A1 (en) 2003-02-27
RU2004111358A (ru) 2005-09-20
EP1344534A2 (en) 2003-09-17
TWI290470B (en) 2007-12-01
CN1615880A (zh) 2005-05-18
CN1615879A (zh) 2005-05-18
CN1263512C (zh) 2006-07-12
KR20020058034A (ko) 2002-07-12
RU2004111359A (ru) 2005-09-20
HK1047239B (en) 2006-12-08
EP1234582A4 (en) 2003-05-07
EP1234582B1 (en) 2006-07-05
ES2267586T3 (es) 2007-03-16
EP1344535A2 (en) 2003-09-17
KR100607430B1 (ko) 2006-08-02
KR20040045028A (ko) 2004-05-31

Similar Documents

Publication Publication Date Title
EP1234582A4 (en) COPRESCRIPTION FOR THE TREATMENT OF GLAUCOMA
EP1074268A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENTS AGAINST INFLAMMABLE DISEASES OF THE DIGESTIVE WAY WITH IL-6 ANTAGONISTS AS ACTIVE INGREDIENTS
AU1095202A (en) Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
EP1108435A4 (en) MEANS FOR PREVENTING OR TREATING PANCREATITIS CONTAINING THE IL-6 ANTAGONISTS AS ACTIVE COMPONENTS
NO20032233L (no) Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer
IL162340A (en) Use of selective modulators for androgen receptor for the preparation of a drug for the treatment of muscle depletion
EA200100519A1 (ru) Композиции на основе тонкоизмельченного эплеренона
NO971546D0 (no) Reumatoid artritt-middel inneholdende IL-6-antagonist som aktiv bestanddel
ATE339425T1 (de) Platelet adp rezeptor inhibitoren
AU9393601A (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
WO2002008186A3 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
WO2004112710A3 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
PT2179987E (pt) Utilização de derivados carbaldeído heterocíclicos contra a anemia falciforme
HUP0302226A3 (en) Substituted pyrrolopyridinone dervatives useful as phosphodiesterse inhibitors, their intermediates and pharmaceutical compositions containing the compounds
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2002064125A3 (en) Use of a farnesoid x receptor antagonist for treating hyperlipidemia
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
HUP0103431A3 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
HU0104085D0 (en) Method for the treatment of pulmonary hypertension
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
WO2002040016A8 (fr) Association d'inhibiteurs de calpaïne et de piegeurs des formes reactives de l'oxygene
WO2005065047A3 (en) Stable oral composition containing desloratadine
WO2002078633A3 (en) Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed